MedTrace Logo

System-IGF-1 Pathway and Alzheimer's Disease

NCT00647478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 693

Last updated 2026-03-11

No results posted yet for this study

Summary

The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild cognitive impairment (MCI).

Conditions

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Olivier Hanon, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-10-31
Completion
2012-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647478 on ClinicalTrials.gov